Tumor Necrosis Factor Blockers

All categories
DBCAT003245Therapeutic category

Compounds or agents that bind to and inhibit the synthesis or activity of TUMOR NECROSIS FACTOR-alpha. Such agents are used to treat inflammatory bowel diseases and other inflammatory diseases. A DrugBank category of 43 drugs. 16 of them are approved.

Also known as
Anti-TNF Agents · Tumor Necrosis Factor Alpha (TNF-α) Inhibitors · Tumor Necrosis Factor Blocker · Tumor Necrosis Factor-alpha, antagonists & inhibitors · Tumour necrosis factor (TNF) alpha inhibitors
Drugs

and 18 more with a free account

What you can answer from here — as of August 03, 2021

43DrugsEach linked to its full drug card
Sign in
81Drug targetsEvery drug–target pair in the class, with bond type
Sign in
9,797Marketed productsAcross the regions we cover, with dosage forms and routes
Sign in
27Routes of administrationHow the drugs in this class are given
Sign in
1SubcategoryNarrower classes within this one
Sign in

Which targets do Tumor Necrosis Factor Blockers share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In